drugset / Trial / NCT01622348
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
Timeline
- Start
- 2012-05
- Primary completion
- 2012-11
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IMO-3100 | Unknown | 0.16 mg/kg | Subcutaneous |
| Comparator | IMO-3100 | Unknown | 0.32 mg/kg | Subcutaneous |